A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

INCLUSION CRITERIA - For Parts 1-4: * Histologically confirmed diagnosis of a locally advanced (not amenable to curative therapy such as surgical resection) or metastatic solid tumors * Life expectancy \> 12 weeks * Patients must not have received prior interleukin-2 (IL-2) therapy * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Measurable disease per RECIST 1.1 * Patients with stable brain metastases under certain criteria * Fresh and archival tumor tissue available Tumor specific inclusion criteria may apply. EXCLUSION CRITERIA - For Parts 1-4: * Use of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR--214 * Females who are pregnant or breastfeeding * Participants who have an active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents * History of organ transplant that requires use of immune suppressive agents * Active malignancy not related to the current diagnosed malignancy * Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis * Participants who have had \< 28 days since the last chemotherapy, biological therapy, or \< 14 days from approved tyrosine kinase inhibitor (TKI) therapy, or systemic or inhaled steroid therapy at doses greater than 10mg of prednisone Tumor specific exclusion criter…